Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00251680 | Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy. | PHASE3 | COMPLETED | 400 | — | — | Oct 1, 2005 | May 1, 2007 | May 24, 2012 | 77 | United States, Czechia +7 |
| Arm | Type | Description |
|---|---|---|
| Lapaquistat Acetate 50 mg QD | EXPERIMENTAL | (and stable lipid-lowering therapy) |
| Stable Lipid-lowering therapy | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Lapaquistat acetate and lipid-lowering therapy | DRUG | Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks. |
| Lipid-lowering therapy | DRUG | Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks. |
Inclusion Criteria: * Females of childbearing potential who are sexually active must agree to use adequate contraception from screening throughout the duration of the study and for 30 days following the last dose. * Has a documented history of dyslipidemia with or without cardiovascular risk factor...